Agonist-antagonist dilemma in molecular imaging: evaluation of a monomolecular multimodal imaging agent for the somatostatin receptor. - Wikidata - awgldk - TriplyDB

Agonist-antagonist dilemma in molecular imaging: evaluation of a monomolecular multimodal imaging agent for the somatostatin receptor.

Agonist-antagonist dilemma in molecular imaging: evaluation of a monomolecular multimodal imaging agent for the somatostatin receptor.

http://www.wikidata.org/entity/Q40050040

about

Fluorescent approaches for understanding interactions of ligands with G protein coupled receptors Dual-labeling strategies for nuclear and fluorescence molecular imaging: a review and analysis Multimodality and nanoparticles in medical imaging Fast 18F labeling of a near-infrared fluorophore enables positron emission tomography and optical imaging of sentinel lymph nodes Phage display in molecular imaging and diagnosis of cancer.Coordinating radiometals of copper, gallium, indium, yttrium, and zirconium for PET and SPECT imaging of disease Multimodality imaging probes: design and challenges.NIR-mbc94, a fluorescent ligand that binds to endogenous CB(2) receptors and is amenable to high-throughput screening.Influence of d-glutamine and d-glutamic acid sequences in optical peptide probes targeted against the cholecystokinin-2/gastrin-receptor on binding affinity, specificity and pharmacokinetic properties.Phage display--a powerful technique for immunotherapy: 1. Introduction and potential of therapeutic applications.Switch from antagonist to agonist after addition of a DOTA chelator to a somatostatin analog Dual PET and Near-Infrared Fluorescence Imaging Probes as Tools for Imaging in Oncology.A practical guide to the construction of radiometallated bioconjugates for positron emission tomography.Preparation and biological evaluation of 64Cu-CB-TE2A-sst2-ANT, a somatostatin antagonist for PET imaging of somatostatin receptor-positive tumors.The role of imaging and molecular imaging in the early detection of metabolic and cardiovascular dysfunctions.Multimodal radio- (PET/SPECT) and fluorescence imaging agents based on metallo-radioisotopes: current applications and prospects for development of new agents.The evolution of imaging in cancer: current state and future challenges.The synthesis and application of polyamino polycarboxylic bifunctional chelating agents.A molecular imaging primer: modalities, imaging agents, and applications.Virus-Derived Peptides for Clinical Applications.Antibody Engineering for Pursuing a Healthier Future A Modular Dual Labeling Scaffold That Retains Agonistic Properties for Somatostatin Receptor Targeting.Three-dimensional fluorescence optical tomography in small-animal imaging using simultaneous positron-emission-tomography priors.Bimodal imaging probes for combined PET and OI: recent developments and future directions for hybrid agent development Multimodal imaging of integrin receptor-positive tumors by bioluminescence, fluorescence, gamma scintigraphy, and single-photon emission computed tomography using a cyclic RGD peptide labeled with a near-infrared fluorescent dye and a radionuclide Characterization of chemical, radiochemical and optical properties of a dual-labeled MMP-9 targeting peptide A functionalized heterobimetallic (99m)Tc/Re complex as a potential dual-modality imaging probe: synthesis, photophysical properties, cytotoxicity and cellular imaging investigations.

P2860

Q27004213-2447F947-AA79-46C9-8324-AEA1F20992C2 Q27027682-72A5A227-BA55-434D-B020-7D473A4CC37D Q30407070-E3839315-15FA-4C2C-A161-778FFCCA67EE Q30497061-C33F9B37-6A06-407D-A5DE-18BBB6DAF0CE Q33532734-6040EC0E-8CAA-4615-99C7-483012F3BAA1 Q33870879-601D538A-95C5-4CDA-AA99-EF0337152213 Q33884695-344A5E96-4689-4AA6-992C-3C47B652013D Q33910732-7BF11292-DF19-43DA-BD01-1563D953E533 Q34250142-1FB8CCF6-1DB8-4752-9A00-ECAA06C8C3C1 Q34385892-9BD87872-4C51-4FB9-A3F1-4140C8177D19 Q34514544-E984EBA7-4581-45F5-99CB-5DEDDF5EC29D Q37120903-1ACF6C38-3DCA-4FA5-84DD-6E5CC151D68E Q37172093-B746BDCA-A4D0-4FF1-82A6-2B4DDE27ABA5 Q37479595-D6FC54B2-BCDE-48C5-B07F-2DA845A6B6DA Q37820086-50F0AB47-97AD-4257-A97C-C1F3AFA573C1 Q37827710-BB60D921-3C3A-4AD7-A2DA-731E87DAB97C Q37848518-87DF96E9-E7E0-443F-9B8B-EA4A13CC0CEF Q37850696-B1E07E2E-E92D-4451-89AD-CDE7F885D1C1 Q38005672-268C9502-14EF-4837-B162-881B384A0959 Q38655270-37AFA88E-5F40-4294-BBE5-59131613FE0C Q38731632-D9418B95-B620-4B9C-8C43-191A71B2A6D1 Q38749965-EE12632C-585A-4539-B92A-7EA7C2BB964B Q40087069-9F8B7AAE-FD67-45A4-8BD7-D55E1E5FAFB4 Q41448000-A8C06D9F-B298-4F7F-9D02-9E2A9B356423 Q41815156-A4FFB1AB-441F-47F0-B2A8-10FC6F355CCE Q42850578-424EA78C-F16E-4F89-A38D-8DD6EFB475BB Q48710259-5BC198F3-E2B0-403F-9DBB-FE9247C0E7D2

P2860

Agonist-antagonist dilemma in molecular imaging: evaluation of a monomolecular multimodal imaging agent for the somatostatin receptor.

http://www.wikidata.org/entity/Q40050040

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

Agonist-antagonist dilemma in ...... for the somatostatin receptor.

@en

type

label

Agonist-antagonist dilemma in ...... for the somatostatin receptor.

@en

prefLabel

Agonist-antagonist dilemma in ...... for the somatostatin receptor.

@en

P1433

Q40050040-B8E4AC5B-77CF-4F37-BA1B-AE9B9771D712

P1476

Q40050040-7959BA15-94D2-4A2E-95A0-54ADBE936EFC

P2093

Q40050040-10EA6D6E-EFC7-43E7-BF91-FE9ABAF3B066

Q40050040-2575BAA5-2264-4917-971F-8D981992D297

Q40050040-B2FB7A46-031A-4DDE-A594-C43EBD7A5D02

Q40050040-BB7B4FA0-6912-44E6-A20D-6D51045E0736

Q40050040-C9BB997B-6286-434D-ADD9-6F112097251E

P2860

Q40050040-0135A607-3198-4D77-A411-80F03479A722

Q40050040-027949D4-5EC6-4CBD-BF07-F949FA947C09

Q40050040-15A74B40-595A-4F02-9BBE-7721606648C9

Q40050040-34092084-927B-44DD-9AA0-87DCBF0639C8

Q40050040-3A395BAE-4A66-4EC8-952A-B95CCCF5464F

Q40050040-431FEF57-10B6-4E06-A0A3-D2B4620CBE7C

Q40050040-4C09FDE9-800C-4A35-A611-B0307796E3A8

Q40050040-536DA93A-6683-4DC9-B9AF-EE2E94540CB7

Q40050040-6421A87E-B459-4914-9CD7-2A59992EEDD6

Q40050040-70A4C11A-5DD2-45E1-A65C-03C4105AD479

P304

Q40050040-D2FE2AC6-9838-4B35-B7DE-CFF2FB828658

P31

Q40050040-48948ACB-EBC7-42F8-B6F7-724DC95745F5

P356

Q40050040-7AF118ED-053A-479C-84F1-C015A7F4E8F6

P433

Q40050040-55712045-58A9-490E-958E-7CA8CACA624C

P478

Q40050040-2AD9CF13-CF27-41DA-B238-80DF37B65BB2

P50

Q40050040-1390392C-4F5E-4C50-AC11-1EF4284E7193

Q40050040-3BB9D4AF-B196-43BC-B355-1A660F397D74

Q40050040-594AF207-F174-43D5-BBF4-C23AA2CCC1ED

P577

Q40050040-82B186C7-D2CB-4C48-AB80-50E8903086F9

P5875

Q40050040-B7CF9907-6010-478F-9422-8DBA8EB3441E

P698

Q40050040-3D3FE1DC-0D50-42D6-98D1-15F92D75F480

P932

Q40050040-06B4E3BB-131B-43A9-9EAD-EF6E68F4CF68

P356

P1433

Bioconjugate Chemistry

P1476

Agonist-antagonist dilemma in ...... for the somatostatin receptor.

@en

P2093

Baogang Xu

http://www.w3.org/2001/XMLSchema#string

Buck E Rogers

http://www.w3.org/2001/XMLSchema#string

Kexian Liang

http://www.w3.org/2001/XMLSchema#string

Philip P Cheney

http://www.w3.org/2001/XMLSchema#string

W Barry Edwards

http://www.w3.org/2001/XMLSchema#string

P2860

Quality analysis of in vivo near-infrared fluorescence and conventional gamma images acquired using a dual-labeled tumor-targeting probe

Novel receptor-targeted fluorescent contrast agents for in vivo tumor imaging.

The pathophysiological consequences of somatostatin receptor internalization and resistance.

Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors.

Molecular imaging in the clinical arena.

Characterization of somatostatin receptor subtype 2 expression in stably transfected A-427 human cancer cells.

Internalization of sst2, sst3, and sst5 receptors: effects of somatostatin agonists and antagonists.

[177Lu-DOTA(0),Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapy.

Toxicity and dosimetry of (177)Lu-DOTA-Y3-octreotate in a rat model.

Synthesis, in vitro receptor binding, and in vivo evaluation of fluorescein and carbocyanine peptide-based optical contrast agents.

P304

192-200

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1021/BC700291M

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P50

Samuel Achilefu

Carolyn J. Anderson

P577

2007-11-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5827466

http://www.w3.org/2001/XMLSchema#string

P698

18020401

http://www.w3.org/2001/XMLSchema#string

P932

2539107

http://www.w3.org/2001/XMLSchema#string